A next-gen Duchenne therapy from Entrada Therapeutics fell short in an early study, as a number of companies race to make improved drugs.
A micrograph from a Duchenne patientAdobe
By Jason Mast
May 7, 2026
General Assignment Reporter
Jason Mast
Alzheimer's drug rollout letdown, a China-based heart drug startup, and more biotech news from The Readout
A closely watched therapy developed by Johnson & Johnson failed to show a statistically meaningful improvement for IBD patients.
Encoded Therapeutics gives a heads-up to other gene therapy company about the trade-offs with a drug meant to improve safety.
Investors are scrutinizing the prospects for some drugs in the pipeline following a string of recent rejections from the U.S.…
A Duchenne therapy lawsuit, FDA Commissioner Marty Makary’s White House troubles, and other news from The Readout
A Cytokinetics heart disease drug — already approved in one indication — succeeded in another Phase 3 trial, a potential boost…
